Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Viridian Therapeutics, Inc. - Common Stock (NQ:VRDN)

16.52 -0.53 (-3.11%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 511,541
Open 17.29
Bid (Size) 16.52 (18)
Ask (Size) 16.53 (1)
Prev. Close 17.05
Today's Range 16.46 - 17.33
52wk Range 9.900 - 27.20
Shares Outstanding 9,587,155
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire

Performance

YTD
-16.4%
-16.4%
1 Month
+10.1%
+10.1%
3 Month
+25.8%
+25.8%
6 Month
-8.9%
-8.9%
1 Year
+14.2%
+14.2%

More News

Read More
Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED)
From Viridian Therapeutics, Inc.
Via Business Wire
Expert Outlook: Viridian Therapeutics Through The Eyes Of 10 Analysts
Via Benzinga
Breaking Down Viridian Therapeutics: 10 Analysts Share Their Views
Via Benzinga
What 5 Analyst Ratings Have To Say About Viridian Therapeutics
Via Benzinga
Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED)
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
In-Depth Examination Of 11 Analyst Recommendations For Viridian Therapeutics
Via Benzinga
Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease
From Viridian Therapeutics, Inc.
Via Business Wire
This C3.ai Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
9 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Tesla, Micron, Broadcom, MARA Holdings And Other Big Stocks Moving Higher On Monday
Via Benzinga
Viridian Therapeutics Skyrockets After Besting Amgen In Thyroid Eye Disease
Via Investor's Business Daily
Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday
Via Benzinga
Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data
From Viridian Therapeutics, Inc.
Via Business Wire

Frequently Asked Questions

Is Viridian Therapeutics, Inc. - Common Stock publicly traded?
Yes, Viridian Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Viridian Therapeutics, Inc. - Common Stock trade on?
Viridian Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Viridian Therapeutics, Inc. - Common Stock?
The ticker symbol for Viridian Therapeutics, Inc. - Common Stock is VRDN on the Nasdaq Stock Market
What is the current price of Viridian Therapeutics, Inc. - Common Stock?
The current price of Viridian Therapeutics, Inc. - Common Stock is 16.52
When was Viridian Therapeutics, Inc. - Common Stock last traded?
The last trade of Viridian Therapeutics, Inc. - Common Stock was at 07/18/25 04:00 PM ET
What is the market capitalization of Viridian Therapeutics, Inc. - Common Stock?
The market capitalization of Viridian Therapeutics, Inc. - Common Stock is 158.38M
How many shares of Viridian Therapeutics, Inc. - Common Stock are outstanding?
Viridian Therapeutics, Inc. - Common Stock has 158M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.